BARDA entered into a partnership with Siemens Healthineers to accelerate development of the SARS-CoV-2 Antigen assay (CoV2Ag)*. BARDA previously funded the Siemens Healthineers ADVIA Centaur SARS-CoV-2 Total (COV2T) assay and the Atellica IM SARS-CoV-2 Total (COV2T) assay antibody test in May 2020.
The CoV2Ag diagnostic test is a chemiluminescent immunoassay in development for the qualitative detection of SARS-CoV-2 antigens in nasal swabs or saliva specimens from individuals with known or suspected exposure to SARS-CoV-2 virus, or who are displaying symptoms suggestive of active viral infection. A high-throughput, automated, laboratory-based antigen test for COVID-19 can screen large numbers of people and deliver results in minutes, rather than the hours required for most molecular tests.
Siemens Healthineers has over 2,000 fully automated immunoassay analyzers in hospitals and mid- to high-volume reference laboratories across all 50 states that could run the CoV2Ag test. Siemens Healthineers immunoassay analyzers include the Atellica IM, which can run up to 440 tests per hour with a result in 10 minutes and the ADVIA Centaur XP and XPT analyzers, which can test up to 240 samples per hour with a result in 18 minutes.
This award is one component of BARDA’s rapidly expanding COVID-19 medical countermeasure portfolio; visit BARDA’s COVID-19 Portfolio to learn more.
* In development. Not available for sale.
About Siemens Healthineers:
The following information is provided by the company and does not indicate endorsement by the federal government of the company or its products.
Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers, which has approximately 54,000 employees worldwide, generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion. Further information is available at www.siemens-healthineers.com.